DPx Launches as Global Provider of Pharmaceutical Services, Fine Chemicals and Proprietary Technologies

DPx Launches as Global Provider of Pharmaceutical Services, Fine Chemicals and 
Proprietary Technologies 
$2.65 Billion Transaction Combines the Capabilities and Expertise of
Patheon and DSM Pharmaceutical Products to Create Industry Powerhouse 
DURHAM, NC  -- (Marketwired) -- 03/11/14 --  DPx Holdings B.V. (DPx),
privately owned by JLL Partners and Royal DSM, today launched as a
leading global contract development and manufacturing organization
(CDMO) for the pharmaceutical and related industries. DPx is the
result of a USD $2.65 billion transaction between JLL Partners, a
leading middle-market private equity firm, and Royal DSM, the global
Life Sciences and Materials Sciences company. DPx is 51 percent owned
by JLL Partners and 49 percent by Royal DSM. With headquarters in
Durham, N.C., DPx's global footprint includes 24 locations across
North America, Europe, Latin America and Australia with more than
8,000 employees. 
Formerly known by its provisional name "NewCo," DPx is the corporate
parent of a group of business units that is comprised of three
distinct brands focused on pharmaceutical services, fine chemicals
and products and proprietary technologies. These units are the result
of combining DSM Pharmaceutical Products (DPP), Patheon and Banner
Life Sciences. The company's business unit structure is as follows: 


 
--  Pharmaceutical services will operate under the Patheon brand name and
    include the commercial manufacturing (CMO) capabilities, pharmaceutical
    product development services (PDS) as well as Biosolutions and Biologics
    (Bio) businesses of DPP;
--  Fine chemicals, or the ES/IM and active pharmaceutical ingredients (API)
    businesses, which will operate under the brand name DSM Fine Chemicals;
    and
--  Proprietary products and technologies, which will operate under the
    Banner Life Sciences brand name.

 
Patheon is the industry's end-to-end supplier providing an integrated
supply chain model to customers. Patheon delivers a full spectrum of
pharmaceutical development and manufacturing services ranging from
active pharmaceutical ingredients (API), Biologics and Biosolutions,
as well as pharmaceutical product development services (PDS) and
commercial manufacturing (CMO) capabilities. Additionally, DSM Fine
Che
micals will handle complicated APIs and finished dosage forms for
customers while Banner Life Sciences will offer its own proprietary
and nutraceutical products to the market. 
"This is an exciting day for our customers and employees. We believe
that combining the capabilities and experience of both Patheon and
DPP immediately positions us as the pharmaceutical industry's partner
of choice," said Jim Mullen, CEO of DPx. "Today we are better
positioned to add scale, new value chain capabilities and
technologies, as well as expand our end-to-end service offerings to
our customers as a global, comprehensive solution provider to the
industry." 
DPx's 2014 sales are anticipated to be about USD $2 billion
(pro-forma). The structure is organized around the customer's needs
and operational efficiency. 
"We are thrilled to announce the close of this landmark deal," said
Paul S. Levy, Managing Director of JLL Partners. "It is the result of
much hard work and strategic foresight and is a demonstration of how
we increase value through investment in growth and market
positioning." 
"We are eager to build on the strong reputation each of our
businesses has with existing customers," said Stefan Doboczky, DPx
board member and member of the DSM Managing Board. "We understand
companies are seeking collaborative relationships with their
suppliers, and we are truly committed to helping them navigate the
challenges posed by the ever-changing nature of the healthcare
marketplace." 
About DPx 
DPx is the privately held parent company of the Patheon, Banner Life
Sciences, and DSM Fine Chemicals businesses. The company is a leading
provider of CDMO services, pharmaceutical products and products for
other industries. Founded in 2014 as a result of a deal between JLL
Partners and Royal DSM, DPx has three core business units, comprised
of Patheon Pharma Services, DSM Fine Chemicals and Banner Life
Sciences. With global headquarters in Durham, N.C., DPx has a
footprint of 24 locations across North America, Europe, Latin America
and Australia with more than 8,000 employees. DPx offers customers
unsurpassed quality, integrated offerings and value through these
three core business units. For more information visit
www.patheon.com/DPx. 
About Patheon  
Patheon is a leading provider of contract development and commercial
manufacturing (CDMO) services to the global pharmaceutical industry
for a full array of solid and sterile dosage forms. Patheon, a DPx
business unit, encompasses the combined CMO capabilities and
pharmaceutical product development services (PDS), as well as the
Biosolutions and Biologics (BIO) business. For more information visit
http://www.patheon.com. 
About DSM Fine Chemicals 
Announced in March 2014 as a business unit under the DPx umbrella,
DSM Fine Chemicals provides active pharmaceutical ingredients (API)
as well as ES/IM products and services that are primarily comprised
of agricultural and crop protection chemicals. Its main focus is
custom synthesis aimed at pharma and fine chemicals markets, of which
the agro-chemicals sector is a primary focus. ES/IM also produces
maleic anhydride and derivatives. 
About Banner Life Sciences 
Banner Life Sciences' mission is to advance human health with
innovation and creativity generating value for society and investors.
Acquired by Patheon in December 2012, Banner Life Sciences is DPx's
proprietary products business. For more information visit
http://www.bannerls.com. 
About JLL Partners 
JLL Partners is a middle-market private equity firm with a 25 year
track-record of adding value to complex investments through financial
and operational expertise. Since its founding in 1988 by Paul S.
Levy, JLL Partners has committed approximately USD 4.2 billion across
six funds, and developed significant expertise in the healthcare and
other sectors. JLL is a control investor and sources its deals from
its deep network of industry contacts, applying its proven,
value-oriented and growth driven investment approach to provide
limited partners with attractive risk-adjusted returns throughout all
investment cycles. For more information visit
http://www.jllpartners.com/. 
About Royal DSM - Bright Science. Brighter Living.â„¢ 
Royal DSM is a global science-based company active in health,
nutrition and materials. By connecting its unique competences in Life
Sciences and Materials Sciences DSM is driving economic prosperity,
environmental progress and social advances to create sustainable
value for all stakeholders. DSM delivers innovative solutions that
nourish, protect and improve performance in global markets such as
food and dietary supplements, personal care, feed, pharmaceuticals,
medical devices, automotive, paints, electrical and electronics, life
protection, alternative energy and bio-based materials. DSM's 23,500
employees deliver annual net sales of around EUR9 billion. The
company is listed on NYSE Euronext. More information can be found at
www.dsm.com. 
SOURCE: Patheon Inc. 
The following files are available for download: 


 
--  Logo Tag 3CLR NEWReg
--  DSM FineChemicalsLogo final
--  BannerLifeSciences LogoOUTL finalTM

  
Contact:
DPx Media Relations
Tel: (919) 226-3200
Email: media@patheon.com
 
 
Press spacebar to pause and continue. Press esc to stop.